

**Dimerix's CSO, A/Prof. Kevin Pflieger, Awarded  
The 2011 3M Eureka Prize for Emerging Leader in Science**

MELBOURNE and PERTH, Australia, 7 September, 2011 – Dimerix is very pleased to announce that on 6 September 2011 Dimerix's CSO, A/Prof. Kevin Pflieger, won the 2011 3M Eureka Prize for Emerging Leader in Science for his work in helping to develop better drugs with fewer side-effects in areas of high disease burden.

This recognition is part of the Australian Museum 2011 Eureka Prizes, the most prestigious awards in Australian science. 'The Eureka's', as they are known, have become the most coveted science awards in Australia. Receiving an Australian Museum Eureka Prize is regarded as a pinnacle achievement for any Australian scientist.

This award recognizes A/Prof. Pflieger's leadership in the field of G protein-coupled receptors, his world-leading expertise in Bioluminescence Resonance Energy Transfer (BRET) technology and his use of the GPCR-HIT technology to find safer and more efficacious drugs.

"We are delighted that Kevin's work and expertise in the GPCR drug discovery field has been recognized by his award of this 2011 Eureka Prize. His leadership in his field of scientific endeavor and the quality of his scientific team is outstanding," said Tim Grogan, Chief Executive Officer of Dimerix Bioscience.

The GPCR-HIT technology was invented by A/Prof. Pflieger and co-workers at the Western Australian Institute for Medical Research and the University of Western Australia. This technology, being commercialized by Dimerix Bioscience, and the group's deep knowledge of the complexes formed by many GPCRs, known as 'GPCR heteromers' lies at the heart of this capability.

Details of the Australian Museum 2011 Eureka Prizes are available [here](#).

**About GPCRs and Dimerix' GPCR-HIT Platform:**

Dimerix' proprietary G Protein-Coupled Receptor Heteromer Identification Technology (GPCR-HIT) platform is used to identify complexes formed by GPCRs known as GPCR heteromers. The platform is also used to screen for and to profile compounds that interact with GPCR heteromers resulting in heteromer-selective or biased pharmacology. Use of GPCR-HIT significantly expands the scope of GPCR-based drug discovery and development through the identification of compounds having biased intracellular signaling that is mediated through the GPCR heteromers.

**About Dimerix Bioscience Pty Ltd:**

Dimerix is a private Australian assay technology and drug discovery company focused on developing pharmaceutical products targeting complexes of GPCRs. Additional information about Dimerix is available through its corporate website, [www.dimerix.com](http://www.dimerix.com).

Dimerix is the recipient of a grant from Commercialisation Australia, [www.commercialisationaustralia.gov.au](http://www.commercialisationaustralia.gov.au).

---

**Contact:**

Tim Grogan, Chief Executive Officer (+61 438 655 452)  
or Dr James Williams, Executive Director (+61 409 050 519)  
Dimerix Bioscience Pty Ltd  
[www.dimerix.com](http://www.dimerix.com)

###